Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Assets (2019 - 2025)

Historic Assets for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $424.0 million.

  • 4D Molecular Therapeutics' Assets fell 2980.76% to $424.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.0 million, marking a year-over-year decrease of 2980.76%. This contributed to the annual value of $560.4 million for FY2024, which is 6487.17% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Assets of $424.0 million as of Q3 2025, which was down 2980.76% from $473.6 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Assets high stood at $629.9 million for Q1 2024, and its period low was $240.6 million during Q3 2021.
  • Moreover, its 5-year median value for Assets was $352.5 million (2023), whereas its average is $390.3 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Assets soared by 15812.7% in 2024 and then tumbled by 2980.76% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Assets stood at $353.5 million in 2021, then fell by 25.92% to $261.8 million in 2022, then rose by 29.81% to $339.9 million in 2023, then soared by 64.87% to $560.4 million in 2024, then fell by 24.34% to $424.0 million in 2025.
  • Its Assets was $424.0 million in Q3 2025, compared to $473.6 million in Q2 2025 and $515.7 million in Q1 2025.